Abbott Laboratories vs Global X CleanTech — how do they compare? Abbott Laboratories trades at $109.69 (market cap $187.95B), while Global X CleanTech trades at $58.44. The key difference: Abbott Laboratories pays a 2.32% dividend while Global X CleanTech pays none. Which is the better fit depends on your goals.
| ABT | CTEC | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $78.11 |
52-Week Low | $82.57 | $41.08 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
CTEC trades at $58.40, up 2.1% today, with a neutral technical signal overall. Moving averages suggest a bullish trend, while oscillators are neutral. The stock faces resistance near $60 and support at $53. A dividend of $0.07 is scheduled for July 2026. Key financial ratios are currently unavailable.
The outlook hinges on upcoming financial disclosures to assess fundamentals. Near-term price action may test resistance at $60. Risks include lack of recent financial data and market volatility. Investor sentiment appears balanced pending further company updates.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →